June 2021
Professor Alexander Eggermont about the potential of Bempegaldesleukin combined with nivolumab as adjuvant treatment
Prof. Alexander Eggermont, Chief Scientific Officer, Princess Máxima Centre, Utrecht, The Netherlands
In this podcast, Prof. Eggermont discusses the results of the PIVOT-12 trial, which investigates the potential of bempegaldesleukin combined with nivolumab as adjuvant treatment after complete melanoma resection in patients with a high risk of recurrence.
SUBSCRIBE TO BJMO ONCOTALKS SERIES
